[EN] TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM [FR] DERIVES DE PYRAZOLE TETRACYCLIQUE UTILISES COMME INHIBITEURS DE KINASE, PROCESSUS DE PREPARATION CORRESPONDANT ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
申请人:Pharmacia Italia S.p.A.
公开号:EP1599202A1
公开(公告)日:2005-11-30
[EN] TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE PYRAZOLE TETRACYCLIQUE UTILISES COMME INHIBITEURS DE KINASE, PROCESSUS DE PREPARATION CORRESPONDANT ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
申请人:PHARMACIA ITALIA SPA
公开号:WO2004071507A1
公开(公告)日:2004-08-26
The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
申请人:Vanotti Ermes
公开号:US20060264493A1
公开(公告)日:2006-11-23
The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.